Hepatitis C in Haematological Patients

الملخص EN

There is no consensus guideline concerning the management of chronic hepatitis C patients during chemotherapy, and immunosuppression.

However, there are some suggestions in literature that hepatitis C viral load increases during chemotherapy and there is a risk of rebound immunity against hepatitis C after discontinuation of immunosuppression with a consequent liver injury.

A close monitoring of liver function of these patients is prudent during treatment of haematological malignancy.

Antiviral treatment is deferred after the completion of chemotherapy and recovery of patients' immunity to minimize the toxicity of treatment.

A combination of pegylated interferon and ribavirin is the standard therapy in hepatitis C infected haematological patients.